The expression of inhibitory CD33-related Siglecs, including human Siglec-7 and Siglec-9 and murine Siglec-E, on tumor-associated macrophages (TAMs) was shown to support cancer progression by driving macrophage polarization toward the tumor-promoting M2 phenotype (9-13). Here, CD33 is linked to neoplasm.